TAS-0612

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameTAS-0612
Drug Alias NameTAS0612TAS-0612
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosomal protein S6 kinase inhibitorsProto-oncogene proteins c-akt inhibitors70-kDa ribosomal protein S6 kinases inhibitors
TargetsRibosomal protein S6 kinaseProto-oncogene proteins c-akt70-kDa ribosomal protein S6 kinases
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaiho Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiho Oncology Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A